Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates
![GlobeNewswire](../../../Content/images/providers/GN.png)
Elicio Therapeutics, Inc. (ELTX)
Company Research
Source: GlobeNewswire
ELI-002 2P Phase 1 preliminary data published in Nature Medicine ELI-002 2P Phase 1 data characterizing the CD4 and CD8 profile of the KRAS immune response and ELI-002-generated antigen spreading presented at the AACR Annual MeetingELI-002 7P Phase 1 preliminary data to be presented at the ASCO Annual Meeting (“ASCO”) in June 2024ELI-002 7P randomized Phase 2 trial enrollment expected to complete in fourth quarter 2024 BOSTON, May 15, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2024, and provided recent corporate and clinical updates. “During the first quarter, we continued to make great progress with our lead program, ELI-002, seeing the first-in-human Phase 1 data on the 2P formulation published in Nature Medicine. We also began enrolling
Show less
Read more
Impact Snapshot
Event Time:
ELTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELTX alerts
High impacting Elicio Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ELTX
News
- Elicio Therapeutics Reports Inducement Grants [Yahoo! Finance]Yahoo! Finance
- Elicio Therapeutics Reports Inducement GrantsGlobeNewswire
- Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual MeetingGlobeNewswire
- Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]Yahoo! Finance
ELTX
Sec Filings
- 6/12/24 - Form EFFECT
- 6/12/24 - Form EFFECT
- 6/3/24 - Form S-3
- ELTX's page on the SEC website